title: Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
abstract: OBJECTIVE
  To determine whether secondary hyperparathyroidism (HPTH) due to hypovitaminosis D affects bone mineral density (BMD) response to alendronate (ALN) in elderly women with osteoporosis.
  
  
  METHODS
  Randomized, controlled trial with 1-year follow-up.
  
  
  METHODS
  Two osteoporosis centers in northern Italy.
  
  
  METHODS
  Community-dwelling women aged 60 and older with a BMD T-score below -2.5 and secondary HPTH with vitamin D insufficiency.
  
  
  METHODS
  One hundred twenty subjects were randomly assigned to receive ALN 70 mg once a week alone or ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily.
  
  
  METHODS
  BMD measured using dual-energy x-ray absorptiometry at the lumbar spine (L1-L4), femoral neck, and total hip and serum levels of intact PTH at baseline and 12 months.
  
  
  RESULTS
  After 1 year, BMD of the lumbar spine, femoral neck, and total hip significantly increased from baseline in both groups (P<.001). Patients allocated to ALN plus 1,25D3 demonstrated a significantly higher increase in lumbar spine BMD than those receiving ALN alone (mean percentage+/-standard deviation 6.8+/-4.6 vs 3.7+/-3.2, P<.001). Serum levels of PTH did not change significantly at 1 year in the ALN group (mean percentage, -3.7+/-27.1, P=.13) but decreased significantly in the ALN plus 1,25D3 group (-32.1+/-22.1, P<.001). At 12 months, subjects with normalized PTH independent of therapy allocation had a greater increase in lumbar spine BMD than those with persistent HPTH (6.5+/-4.6% vs 3.7+/-3.4%, P<.001). Lumbar spine BMD changes showed a significant negative correlation with PTH at 1 year (correlation coefficient (rho) =-0.399, P<.001) and a positive correlation with PTH changes (i.e., baseline value - 1 year value; rho=0.295, P=.005).
  
  
  CONCLUSIONS
  Persistence of secondary HPTH reduces BMD response to ALN in older women with osteoporosis.
authors.affiliation: Department of Gerontology and Musculoskeletal Sciences, Galliera Hospital, Genoa, Italy. antonella.barone@galliera.it
authors.forename: Antonella
authors.initials: A
authors.lastname: Barone
authors.forename: Andrea
authors.initials: A
authors.lastname: Giusti
authors.forename: Giulio
authors.initials: G
authors.lastname: Pioli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Girasole
authors.forename: Monica
authors.initials: M
authors.lastname: Razzano
authors.forename: Monica
authors.initials: M
authors.lastname: Pizzonia
authors.forename: Ernesto
authors.initials: E
authors.lastname: Palummeri
authors.forename: Gerolamo
authors.initials: G
authors.lastname: Bianchi
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology* / Q000378:metabolism; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D014808:Vitamin D Deficiency / Q000150:complications* / Q000188:drug therapy
chemical_list: D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D002117:Calcitriol; D002118:Calcium; D019386:Alendronate